Pharmaceuticals

Global End Stage Renal Disease (ESRD) Drug Market Size Projected to Reach $262.76 Billion During the Forecast Period

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The End Stage Renal Disease (ESRD) Drug Industry Compare Between 2025 And 2029?

The end stage renal disease (esrd) drug market size has observed swift growth in recent years. It is expected to climb from $131.41 billion in 2024 to $148.55 billion in 2025, at a compound annual growth rate (CAGR) of 13.0%. The expansion experienced in earlier periods is linked to the rising incidence of end stage renal disease, an expanding aging demographic, better access to healthcare provisions, various government initiatives and policies, and the increasing embrace of renal replacement therapies.

The end stage renal disease (esrd) drug market size is poised for substantial growth in the upcoming years. It is predicted to expand to $262.76 billion by 2029, achieving a compound annual growth rate (CAGR) of 15.3%. This anticipated growth is primarily fueled by the advent of new therapies and pharmaceutical innovations, increasing spending within the healthcare sector, the escalating worldwide prevalence of chronic kidney diseases, the adoption of personalized medicine techniques, and robust regulatory backing combined with streamlined approval processes. Significant trends during this forecast period encompass a rising incidence of end stage renal disease, continuous advancements in treatment options, a heightened focus on precision medicine, the development of multi-drug combination therapies, and the increasing integration of technology into healthcare practices.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp

What Are The Main Drivers Boosting The End Stage Renal Disease (ESRD) Drug Industry’s Expansion?

The escalating instances of obesity and diabetes are anticipated to stimulate the expansion of the end-stage renal disease (ESRD) drug market moving forward. Obesity is characterized as an abnormal or excessive accumulation of fat that poses health risks. In contrast, diabetes is a chronic condition that arises either when the pancreas does not produce sufficient insulin or when the body is unable to effectively utilize the insulin it generates. For patients with renal disease, managing fluid and electrolyte levels, blood pressure, and eliminating waste products through dialysis can enhance overall health and well-being, potentially leading to weight reduction and improved blood sugar control. For instance, in March 2022, World Obesity, a US-based membership organization representing national and regional associations dedicated to the study and management of obesity, stated that the number of obese people is expected to increase to 892 million in 2025 and then to 1,025 million in 2030. Furthermore, in February 2023, according to the National Health Service, the UK-based publicly funded healthcare system, it is estimated that by 2030, the number of people in the UK with diabetes could reach 5.5 million, impacting nearly 9% of the population. Therefore, the increasing prevalence of obesity and diabetes will drive the market for end-stage renal disease (ESRD) drugs.

What Are The Different Segment Classifications Within The End Stage Renal Disease (ESRD) Drug Market?

The end stage renal disease (esrd) drug market covered in this report is segmented –

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products

2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol

3) By Sterols: Ergocalciferol, Cholecalciferol

4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate

5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate

6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents

Which Competitive Trends Are Defining The End Stage Renal Disease (ESRD) Drug Market Structure?

Product innovation represents a key trend enhancing popularity within the end-stage renal disease (ESRD) drug market. Leading companies in the end-stage renal disease (ESRD) drug market are primarily focused on creating innovative solutions to maintain their position. As an example, in April 2022, GlaxoSmithKline PLC, a UK-based pharmaceutical and biotechnology firm, announced that the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for daprodustat. This oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is intended for the potential treatment of patients suffering from chronic kidney disease anemia (CKD). The foundation of this new product lies in unique Nobel prize-winning science that demonstrated how cells sense and adapt to oxygen availability.

Which Leading Companies Dominate The End Stage Renal Disease (ESRD) Drug Market Share?

Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

How Do Regional Market Performances Compare Within The End Stage Renal Disease (ESRD) Drug Industry?

North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The End Stage Renal Disease (ESRD) Drug Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp

Browse Through More Reports Similar to the Global End Stage Renal Disease (ESRD) Drug Market 2025, By The Business Research Company

Cardiovascular Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795